Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 08/05/25
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)GlobeNewsWire • 06/23/25
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human PrimatesGlobeNewsWire • 06/18/25
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025GlobeNewsWire • 06/13/25
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 06/03/25
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute LeukemiaGlobeNewsWire • 05/14/25
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate HighlightsGlobeNewsWire • 05/05/25
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)Zacks Investment Research • 04/02/25
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/01/25
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)Zacks Investment Research • 04/01/25
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 03/31/25
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)Zacks Investment Research • 03/31/25
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last DoseGlobeNewsWire • 03/24/25
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for DiabetesGlobeNewsWire • 02/27/25
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesGlobeNewsWire • 12/17/24
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)GlobeNewsWire • 12/16/24
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewsWire • 12/12/24
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaGlobeNewsWire • 12/09/24
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaGlobeNewsWire • 12/06/24